Coenzyme Q10 for Acute Stanford Type A Aortic Dissection: Protocol for a Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Feasibility Trial
- 1Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
- 2Department of Epidemiology, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, China
Abstract
Background/Objectives: Acute Stanford type A aortic dissection (TAAD) is a catastrophic cardiovascular emergency. Emergency surgery is the standard life-saving treatment, but some patients decline operative repair, and no established pharmacological therapy has been shown to stabilize acute TAAD. Preclinical work by our team implicates mitochondrial dysfunction and smooth muscle cell phenotypic switching in aortic dissection and suggests that coenzyme Q10 may reduce dissection-related injury. This study aims to determine the feasibility of a future definitive randomized trial and to obtain preliminary safety and exploratory efficacy information. Methods: This prospective, randomized, double-blind, placebo-controlled, single-center feasibility trial will enroll 60 adults with CTA-confirmed Stanford type A aortic dissection within 24 h of symptom onset who decline emergency surgical repair after standard surgical counseling. Participants will be randomized 1:1 to oral coenzyme Q10 100 mg three times daily or matched placebo for 14 days, in addition to the same guideline-directed supportive medical care. The primary feasibility outcome is recruitment feasibility, defined as randomization of 60 participants within 12 months after recruitment initiation. Secondary feasibility outcomes include treatment adherence, follow-up completion, dropout, missingness, outcome-assessment feasibility, and candidate endpoint event rates. The primary exploratory clinical outcome is 14-day all-cause mortality; additional exploratory outcomes include aortic rupture death, false-lumen thrombosis, cardiac tamponade, worsening pericardial effusion, and organ malperfusion syndromes. Safety outcomes include adverse events, serious adverse events, adverse drug reactions, suspected unexpected serious adverse reactions, and prespecified laboratory indices. Results: The trial is designed to establish whether recruitment, blinded treatment delivery, follow-up, outcome collection, and safety monitoring are operationally feasible and to provide estimates for planning a larger confirmatory trial. Conclusions: This feasibility trial will inform the design and conduct of future definitive evaluation of coenzyme Q10 in acute TAAD. Trial registration: Chinese Clinical Trial Registry, ChiCTR2600123230.
Related
- Pilot Feasibility Study of a Community Health Worker-delivered Tobacco Cessation Intervention During Pregnancy: The Smoke-Free HOPE Randomized Controlled Trial
- Feasibility and acceptability of a randomized controlled trial of a patient-centred transition program for stroke survivors and their caregivers—P-NAVISTROKE study
- Feasibility, Safety, and Preliminary Efficacy of Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease: A 12-Month Pilot Randomized Controlled Trial
- Vitamin D screening and targeted supplementation delays liver fibrosis in patients with chronic liver disease: A prospective randomized controlled trial
- Effects of pentoxifylline on cognitive deficits in cerebral small vessel disease: a prospective, randomized controlled, multi-center trial protocol
BibTeX
@article{dai2026coenzyme,
title = {{Coenzyme Q10 for Acute Stanford Type A Aortic Dissection: Protocol for a Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Feasibility Trial}},
author = {Lu Dai and Shi-Pan Wang and Yin-Fan Zhu and Hao-Tian Wu and Bao-Fu Zheng and Hai-Yang Li and Wen-Jian Jiang and Hong-Jia Zhang},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208103},
url = {https://www.mdpi.com/2077-0383/15/20/8103},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Coenzyme Q10 for Acute Stanford Type A Aortic Dissection: Protocol for a Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Feasibility Trial
AU - Lu Dai
AU - Shi-Pan Wang
AU - Yin-Fan Zhu
AU - Hao-Tian Wu
AU - Bao-Fu Zheng
AU - Hai-Yang Li
AU - Wen-Jian Jiang
AU - Hong-Jia Zhang
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208103
UR - https://www.mdpi.com/2077-0383/15/20/8103
AB - Background/Objectives: Acute Stanford type A aortic dissection (TAAD) is a catastrophic cardiovascular emergency. Emergency surgery is the standard life-saving treatment, but some patients decline operative repair, and no established pharmacological therapy has been shown to stabilize acute TAAD. Preclinical work by our team implicates mitochondrial dysfunction and smooth muscle cell phenotypic switching in aortic dissection and suggests that coenzyme Q10 may reduce dissection-related injury. This study aims to determine the feasibility of a future definitive randomized trial and to obtain preliminary safety and exploratory efficacy information. Methods: This prospective, randomized, double-blind, placebo-controlled, single-center feasibility trial will enroll 60 adults with CTA-confirmed Stanford type A aortic dissection within 24 h of symptom onset who decline emergency surgical repair after standard surgical counseling. Participants will be randomized 1:1 to oral coenzyme Q10 100 mg three times daily or matched placebo for 14 days, in addition to the same guideline-directed supportive medical care. The primary feasibility outcome is recruitment feasibility, defined as randomization of 60 participants within 12 months after recruitment initiation. Secondary feasibility outcomes include treatment adherence, follow-up completion, dropout, missingness, outcome-assessment feasibility, and candidate endpoint event rates. The primary exploratory clinical outcome is 14-day all-cause mortality; additional exploratory outcomes include aortic rupture death, false-lumen thrombosis, cardiac tamponade, worsening pericardial effusion, and organ malperfusion syndromes. Safety outcomes include adverse events, serious adverse events, adverse drug reactions, suspected unexpected serious adverse reactions, and prespecified laboratory indices. Results: The trial is designed to establish whether recruitment, blinded treatment delivery, follow-up, outcome collection, and safety monitoring are operationally feasible and to provide estimates for planning a larger confirmatory trial. Conclusions: This feasibility trial will inform the design and conduct of future definitive evaluation of coenzyme Q10 in acute TAAD. Trial registration: Chinese Clinical Trial Registry, ChiCTR2600123230.
SN - 2077-0383
ER -